No, not the one on NWBO. I opted to write that one since it's been over a year since the last time I did.
Currently I am writing an article on Mersana Therapeutics that will likely be published sometime tomorrow. Last request was one for Protara on the back of their reported positive phase 3 trial.
The people who are on the outreach team offer no insight into Seeking Alpha having some stance. Here is a transcript of the latest request, consistent with the others I receive:
Hi ****,
Hi REDACTED,
Apologies. I was on vacation last week and I couldn't reply to you.
I noticed that your CMRX article was published on Dec. 11.
Would you be interested in updating your thesis on Mersana Therapeutics (MRSN)? Let me know what you think.
Thanks.
Best,
REDACTED
The times I've gotten pushback has been when I did not have much material to update on. Never has the fact that I was positive or negative on a stock was that the reason why it needed a change. Only article to be rejected was one on GLYC post-trial failure since it was too low a market cap